Why the study?
Uncomplicated T1DM displays features of subclinical CVD, and miR-200c-3p is known to be pro-atherogenic in animal tissues, but its role in T1DM remained unexplored.
Downregulation of miR-200c-3p in PBMCs of patients with type 1 diabetes correlates with poor glycemic control, inflammation, and reduced vascular health, suggesting its potential as a biomarker for subclinical cardiovascular disease.
Answers are grounded in this paper and cite their sources.
Downregulated miR-200c-3p in T1DM correlates with vascular markers; leaves open its biomarker utility for subclinical CVD.
Uncomplicated type 1 diabetes (T1DM) displays all features of subclinical cardiovascular disease (CVD) as is associated with inflammation, endothelial dysfunction and low endothelial progenitor cells. MiR-200c-3p has been shown in animal tissues to be pro-atherogenic. We aimed to explore the role of miR-200c-3p in T1DM, a model of subclinical CVD. 19 samples from T1DM patients and 20 from matched controls (HC) were analyzed. MiR-200c in plasma and peripheral blood mononuclear cells (PBMCs) was measured by real-time quantitative polymerase chain reaction. The results were compared with the following indices of vascular health: circulating endothelial progenitor cells, (CD45dimCD34+VEGFR-2+ or CD45dimCD34+CD133+) and proangiogenic cells (PACs). MiR-200c-3p was significantly downregulated in PBMCs but not in plasma in T1DM. There was a significant negative correlation between the expression of miR-200c-3p and HbA1c, interleukin-7 (IL-7), vascular endothelial growth factor-C (VEGF-C), and soluble vascular cell adhesion molecule-1, and a positive correlation with CD45dimCD34+VEGFR-2+, CD45dimCD34+CD133+ and PACs. Receiver operating curve analyses showed miR-200c-3p as a biomarker for T1DM with significant downregulation of miR-200c-3p, possibly defining subclinical CVD at HbA1c > 44.8 mmol/mol (6.2%). In conclusion, downregulated miR-200c-3p in T1DM correlated with diabetic control, VEGF signaling, inflammation, vascular health and targeting VEGF signaling, and may define subclinical CVD. Further prospective studies are necessary to validate our findings in a larger group of patients.
No takes yet. Share an insight, caveat, or question.
Bakhashab et al. (2022) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: